Pharmacokinetics and Toxicities after Evomela® (propylene glycol free melphalan) with Autologous Hematopoietic Stem Cell Transplant (AHCT) for Multiple Myeloma and AL Amyloidosis

Background: Melphalan exposure as measured by area under the curve (AUC) has a 5-fold variability between patients, with higher AUCs associated with improved outcomes but increased toxicity (Shaw BBMT 2012). Propylene glycol free melphalan (Evomela®, PGF-MEL) is an intravenous formulation with improved stability and possibly less toxicity related to the solubilizing agent. We have switched to PGF-MEL as conditioning prior to AHCT for multiple...